Multidisciplinary Hospital For Active Treatment Haskovo AD

The Multidisciplinary Hospital For Active Treatment Haskovo AD conducts a focused program of clinical research aimed at improving outcomes for patients with cardiovascular diseases. Trials investigate new anticoagulant agents, strategies to prevent recurrent ischemic events after heart attacks or strokes, and innovative approaches to manage bleeding during urgent procedures.

• Anticoagulant therapy for atrial fibrillation
• Prevention of recurrent ischemic stroke after acute non‑cardioembolic events
• Management of bleeding risk in patients requiring urgent surgery
• Lipid‑lowering interventions for severe hypertriglyceridemia
• Evaluation of novel FXIa inhibitors for major adverse cardiovascular events

With 7 active trials and a team of 9 investigators, the site seeks to test new therapies that could reduce the risk of major adverse cardiovascular events and improve safety profiles for patients with conditions such as acute coronary syndrome, atrial fibrillation, and ischemic stroke.

Although the primary emphasis is on cardiovascular health, the hospital also explores inherited metabolic disorders that influence heart disease risk, including studies on severe hypertriglyceridemia as a genetic lipid abnormality.

• Genetic forms of hypertriglyceridemia
• Inherited risk factors for atherosclerotic cardiovascular disease

These investigations aim to evaluate targeted treatments that could modify disease progression in patients with hereditary lipid disorders, supporting the broader mission of reducing cardiovascular complications linked to genetic factors.